U.S. markets open in 8 hours 7 minutes
  • S&P Futures

    4,434.25
    +1.25 (+0.03%)
     
  • Dow Futures

    34,798.00
    +55.00 (+0.16%)
     
  • Nasdaq Futures

    15,166.00
    -28.75 (-0.19%)
     
  • Russell 2000 Futures

    2,283.90
    +6.90 (+0.30%)
     
  • Crude Oil

    76.02
    +0.57 (+0.76%)
     
  • Gold

    1,751.70
    -0.30 (-0.02%)
     
  • Silver

    22.66
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1704
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    18.76
    +1.01 (+5.69%)
     
  • GBP/USD

    1.3716
    +0.0011 (+0.08%)
     
  • USD/JPY

    111.1800
    +0.2020 (+0.18%)
     
  • BTC-USD

    42,605.82
    -1,595.17 (-3.61%)
     
  • CMC Crypto 200

    1,055.54
    -45.98 (-4.17%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,123.78
    -116.28 (-0.38%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATER, RLX and ATHA

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 5, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Aterian, Inc. (NASDAQ:ATER)
Class Period: December 1, 2020 - May 3, 2021
Lead Plaintiff Deadline: July 12, 2021

According to the complaint, Aterian, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ATER: https://www.kleinstocklaw.com/pslra-1/aterian-inc-loss-submission-form?id=17402&from=1

RLX Technology Inc. (NYSE:RLX)
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021

The RLX lawsuit alleges that throughout the class period, RLX Technology Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.

Learn about your recoverable losses in RLX: https://www.kleinstocklaw.com/pslra-1/rlx-technology-inc-loss-submission-form?id=17402&from=1

Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline: August 24, 2021

The complaint alleges Athira Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

Learn about your recoverable losses in ATHA: https://www.kleinstocklaw.com/pslra-1/athira-pharma-inc-loss-submission-form?id=17402&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/654272/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ATER-RLX-and-ATHA